Basis of Presentation (Tables)

12 Months Ended

Dec. 31, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Cash and Cash Equivalents

The following table provides a reconciliation of cash, cash equivalents and restricted cash as reported within the Consolidated Balance Sheets to "Cash, cash equivalents and restricted cash at the end of the period" as reported within the Consolidated Statements of Cash Flows:

	Successor		Predecessor
In thousands	December 31, 2020		December 31, 2019
Cash and cash equivalents	$	17,474	$	3,137
Restricted cash, current	8,972		—
Total cash, cash equivalents and restricted cash shown in the Consolidated Statements of Cash Flows	$	26,446	$	3,137

Restrictions on Cash and Cash Equivalents

The following table provides a reconciliation of cash, cash equivalents and restricted cash as reported within the Consolidated Balance Sheets to "Cash, cash equivalents and restricted cash at the end of the period" as reported within the Consolidated Statements of Cash Flows:

	Successor		Predecessor
In thousands	December 31, 2020		December 31, 2019
Cash and cash equivalents	$	17,474	$	3,137
Restricted cash, current	8,972		—
Total cash, cash equivalents and restricted cash shown in the Consolidated Statements of Cash Flows	$	26,446	$	3,137

Schedule of Antidilutive Securities

The following securities were excluded from the computation of diluted net loss per share, as their effect would have been antidilutive:

	Successor	Predecessor
	Month Ended December 31, 2020	Eleven Months Ended November 30, 2020	Year Ended December 31, 2019
Preferred stock	—	17,173,272	15,828,683
Warrants	1,111,110	760,000	760,000
Stock appreciation rights	—	1,010,000	1,010,000
Restricted stock units	—	1,344,006	1,555,676